封面
市场调查报告书
商品编码
1663152

脂质体阿霉素市场规模、份额和成长分析(按产品类型、应用、分销管道和地区)- 2025-2032 年产业预测

Liposomal Doxorubicin Market Size, Share, and Growth Analysis, By Product Type (Lipodox, Doxil), By Application (Breast Cancer, Ovarian Cancer), By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2023 年全球脂质体阿霉素市场规模价值为 12 亿美元,预计将从 2024 年的 12.8 亿美元成长到 2032 年的 21 亿美元,预测期间(2025-2032 年)的复合年增长率为 6.4%。

由于肉瘤发病率的上升以及该药物在治疗乳腺癌、卵巢癌和卡波西氏肉瘤等各种癌症中的应用,脂质体阿霉素市场正在经历强劲增长。这种脂质体包裹的化疗溶液受益于现代医疗保健的进步、医疗成本的上升以及患者对治疗方案的认识的提高。儘管学名药的竞争和 FDA 的严格核准程序仍是挑战,但由于公共和私营部门的投资增加,预计整体市场将会扩大。此外,肝细胞癌发病率和存活率的上升,以及对传统治疗无反应的患者对有效替代疗法的需求不断增长,进一步刺激了对脂质体阿霉素的需求,预计这将推动市场在未来几年大幅增长。

目录

介绍

  • 调查目的
  • 研究范围
  • 定义

调查方法

  • 资讯采购
  • 次要和主要资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分机会分析

市场动态及展望

  • 市场概况
  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特的分析

主要市场考察

  • 关键成功因素
  • 竞争程度
  • 主要投资机会
  • 市场生态系统
  • 市场吸引力指数(2024 年)
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析
  • 案例研究
  • 监管格局
  • 专利分析

脂质体阿霉素市场规模(按产品类型和复合年增长率) (2025-2032)

  • 市场概况
  • 脂质体
  • Doxil
  • Mio 套装

脂质体阿霉素市场规模(按应用和复合年增长率) (2025-2032)

  • 市场概况
  • 乳癌
  • 卵巢癌
  • 多发性骨髓瘤
  • 卡波西氏肉瘤
  • 其他癌症

脂质体阿霉素市场规模(按分销管道和复合年增长率) (2025-2032)

  • 市场概况
  • 医院药房
  • 零售药局
  • 网路药局

脂质体阿霉素市场规模(按地区)及复合年增长率(2025-2032)

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲国家
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前 5 家公司对比
  • 主要企业市场定位(2024年)
  • 主要市场参与者所采用的策略
  • 近期市场趋势
  • 公司市场占有率分析(2024 年)
  • 主要企业简介
    • 公司详细信息
    • 产品系列分析
    • 公司分部份额分析
    • 收益与前一年同期比较对比(2022-2024 年)

主要企业简介

  • Johnson & Johnson(USA)
  • Sun Pharmaceutical Industries Ltd.(India)
  • Pfizer Inc.(USA)
  • Merck & Co., Inc.(USA)
  • Cipla Inc.(India)
  • Cadila Pharmaceuticals(India)
  • SRS Pharmaceuticals Pvt. Ltd.(India)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Gilead Sciences, Inc.(USA)
  • Baxter International Inc.(USA)
  • Novartis AG(Switzerland)
  • F. Hoffmann-La Roche AG(Switzerland)
  • Bristol-Myers Squibb Company(USA)
  • Mylan NV(USA)
  • Sanofi SA(France)
  • Eli Lilly and Company(USA)
  • GlaxoSmithKline plc(UK)
  • AstraZeneca plc(UK)
  • Amgen Inc.(USA)
  • Takeda Pharmaceutical Company Limited(Japan)

结论和建议

简介目录
Product Code: SQMIG35I2216

Global Liposomal Doxorubicin Market size was valued at USD 1.2 billion in 2023 and is poised to grow from USD 1.28 billion in 2024 to USD 2.1 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

The liposomal doxorubicin market is experiencing robust growth driven by the rising incidence of sarcoma and the drug's use in treating various cancers such as breast, ovarian, and Kaposi sarcoma. This chemotherapy solution, encapsulated in liposomes, benefits from modern healthcare advancements, increased healthcare expenditures, and heightened patient awareness regarding treatment options. While competition from generic medications and stringent FDA approval processes pose challenges, overall market expansion is anticipated due to growing investment from both public and private sectors. Additionally, the escalating need for effective alternatives for patients unresponsive to traditional treatments, alongside the rising incidence and survival rates of hepatocellular carcinoma, further stimulates demand for liposomal doxorubicin, positioning the market for substantial growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liposomal Doxorubicin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liposomal Doxorubicin Market Segments Analysis

Global Liposomal Doxorubicin Market is segmented by Product Type, Application, Distribution Channel and region. Based on Product Type, the market is segmented into Lipodox, Doxil and Myocet. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, Multiple Myeloma, Kaposi's Sarcoma and Other Cancers. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liposomal Doxorubicin Market

The Global Liposomal Doxorubicin market is predominantly driven by its application in the treatment of breast cancer, a disease that is rapidly escalating in prevalence across the globe. The surge in innovative formulations has significantly enhanced the drug's appeal and adoption for breast cancer therapy. Several other factors are expected to propel market growth in the coming years, including a rising demand for targeted therapies, increased utilization of chemotherapy, and heightened investments from private sectors focused on this treatment. Additionally, robust government support for the healthcare industry plays a vital role in advancing the market's global expansion.

Restraints in the Global Liposomal Doxorubicin Market

The global liposomal doxorubicin market could face limitations due to potential adverse effects associated with the medication. Patients may experience various complications such as an increased risk of infections, difficulty in breathing, pallor, unexplained bruising, frequent nosebleeds, fatigue, and weakness both prior to and following treatment. Additionally, symptoms such as painful red or peeling skin on the hands and feet, significant weight loss, diarrhea, and generalized weariness may arise. These side effects could result in hesitancy among patients and healthcare providers, ultimately restraining the market's growth and acceptance in the treatment landscape.

Market Trends of the Global Liposomal Doxorubicin Market

The Global Liposomal Doxorubicin market is witnessing significant growth, driven primarily by the increasing incidence of breast cancer, which accounts for one in four female cancer diagnoses globally, according to the International Agency for Research on Cancer (IARC). As liposomal formulations enhance the therapeutic efficacy and reduce the cardiotoxicity associated with conventional doxorubicin, they are gaining traction among oncologists and patients alike. Innovations in drug delivery systems, coupled with rising healthcare expenditures and a surge in awareness regarding targeted cancer therapies, position liposomal doxorubicin as a preferred choice in chemotherapeutic regimens, effectively meeting the growing demand for safer and more effective cancer treatments worldwide.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies
  • Regulatory Landscape
  • Patent Analysis

Global Liposomal Doxorubicin Market Size by Product Type & CAGR (2025-2032)

  • Market Overview
  • Lipodox
  • Doxil
  • Myocet

Global Liposomal Doxorubicin Market Size by Application & CAGR (2025-2032)

  • Market Overview
  • Breast Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Kaposi's Sarcoma
  • Other Cancers

Global Liposomal Doxorubicin Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Liposomal Doxorubicin Market Size & CAGR (2025-2032)

  • North America (Product Type, Application, Distribution Channel)
    • US
    • Canada
  • Europe (Product Type, Application, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Product Type, Application, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Product Type, Application, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Product Type, Application, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cipla Inc. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cadila Pharmaceuticals (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • SRS Pharmaceuticals Pvt. Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations